01
Overview
Salaras is a clinical-stage biotechnology company focused on the development of novel small molecule inhibitors for the treatment of cancer. The company's lead program, SAL-003, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor currently being evaluated in Phase 1 clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML) and other hematologic malignancies. Salaras aims to address significant unmet medical needs in oncology by targeting key regulatory pathways involved in tumor cell survival and proliferation. The company is also exploring the potential of its CDK9 inhibitor in various solid tumor indications, leveraging its precision medicine approach to improve patient outcomes.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on SALARAS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SALARAS.